Medicine and Dentistry
Uterine Cancer
100%
Gynecological Oncology
49%
Neoplasm
47%
Overall Survival
44%
Diseases
41%
Ovarian Cancer
40%
Malignant Neoplasm
33%
Cervical Cancer
29%
Recurrent Disease
27%
Oncology
26%
Endometrium Carcinoma
23%
Cancer
22%
Progression Free Survival
19%
Radiation Therapy
17%
Carcinosarcoma
17%
Positron Emission Tomography
16%
Pelvis
15%
Adjuvant Therapy
15%
Paclitaxel
14%
Krukenberg Tumor
13%
Carboplatin
13%
Female Genital Tract Cancer
13%
Microsatellite Instability
12%
Metastatic Carcinoma
12%
Hazard Ratio
11%
Body Mass Index
11%
DNA Mismatch Repair
11%
Bevacizumab
11%
Fallopian Tube
10%
Brachytherapy
9%
Intensity Modulated Radiation Therapy
9%
Clinical Trial
9%
Kaplan Meier Method
9%
Lymph Node
8%
Disease Free Survival
7%
Cisplatin
7%
Connective Tissue Cancer
7%
Gynecology
7%
Recurrent Ovarian Cancer
7%
Fluorodeoxyglucose
7%
Chemoradiotherapy
7%
Adenocarcinoma
7%
Uterine Cervix Carcinoma
7%
Hereditary Nonpolyposis Colorectal Cancer
7%
Lymph Node Metastasis
6%
Multivariate Analysis
6%
Surgery
6%
Combination Therapy
6%
Hysterectomy
6%
Wound Complication
6%
Keyphrases
Endometrial Cancer
66%
Overall Survival
42%
Ovarian Cancer
30%
NRG Oncology
30%
Chemotherapy
30%
Tumor
28%
Gynecologic Oncology Group
28%
Gynecologic Oncology
24%
Cervical Cancer
21%
Group Studies
20%
Recurrent Endometrial Cancer
20%
Microsatellite Instability-high (MSI-H)
17%
Progression-free Survival
17%
Carboplatin
17%
Confidence Interval
16%
Hazard Ratio
15%
Paclitaxel
15%
Endometrial Carcinoma
14%
Uterine Carcinosarcoma
14%
Uterine Serous Carcinoma
14%
Bevacizumab
14%
Adjuvant Therapy
14%
Endometrioid
13%
Oncology Patients
13%
Cisplatin
12%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
10%
Endometrioid Endometrial Cancer
10%
Positron Emission Tomography
10%
Gynecological Cancer
10%
Body Mass Index
9%
Recurrent Ovarian Cancer
9%
Radiation Therapy
9%
Cervical Carcinoma
9%
Mismatch Repair
9%
Survival Outcomes
9%
Fallopian Tube
8%
Intensity-modulated Radiation Therapy
8%
Epithelial Ovarian Cancer
8%
Brachytherapy
8%
Cervical Cancer Patients
8%
Primary Peritoneal Cancer
8%
Cancer Patients
8%
Clinical Outcomes
8%
Carboplatin-paclitaxel
7%
Phase II Trial
7%
Dostarlimab
7%
Immunohistochemistry
7%
Uterine Cancer
7%
Disease-free Survival
7%
Gynecologic Malignancies
7%